Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
First Claim
Patent Images
1. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
0 Assignments
0 Petitions
Accused Products
Abstract
N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agent selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents.
57 Citations
90 Claims
- 1. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
- 26. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal an anti-hepatitis virus effective amount of an antiviral composition comprising at least one N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof
-
54. An N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
- 55. A compound as set forth in claim 543 wherein R is selected from the group consisting of monohaloalkyl, a substituent corresponding to R5 and haloalkoxyalkyl.
- 58. A pharmaceutical composition comprising an antiviral compound comprising an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound or a pharmaceutically acceptable salt thereof and another antiviral compound selected from the group consisting of a nucleoside, a nucleotide, an immunomodulator, an immunostimulant, and mixtures thereof, said N-substitutted-1,5-dideoxy-1,5-imino-D-glucitol compound corresponding to Formula I:
- 63. A salt of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound and an antiviral compound selected from the group consisting of a nucleoside having an acid moiety and a nucleotide, said N-substitutted-1,5-dideoxy-1,5-imino-D-glucitol compound corresponding to Formula I:
- 68. A pharmaceutical composition comprising N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
- 69. A method for treating a hepatitis virus infection in a mammal, comprising administering to said mammal a first amount of at least one substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
- 79. A pharmaceutical composition comprising an anti-hepatitis effective amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
- 83. An N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
-
85. An N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
- 87. An N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
- 89. An N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I or a pharmaceutically acceptable salt thereof:
Specification